LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock des

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally inv

AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood f

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 P

U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medi

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock.

ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends suppo

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock.

AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) has been assigned a consensus recommendation of

The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in An

The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in ove

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is re

AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers

AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patien

AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 third-quarter results that management described as

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Es

AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) v

AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst co

Stocks end higher, Fear & Greed Index eases, Trump suggests quick military withdrawal from Iran,

U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Cor

Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Optio

Fiscal Year 2026 Financial GuidanceFor fiscal year 2026 the company now expects:Guidance Metric Guid

U.S. stock futures up, focus on AngioDynamics, Microchip Tech, AAR earnings. Galapagos to wind down

U.S. stocks rise on Venezuela raids, Dow hits record high. CNN Money Fear and Greed Index improves b

AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow e

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and r

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures o

CNN Business Fear & Greed Index at 52.3, remaining in Neutral zone. Stocks close higher despite

US stock futures mixed, with attention on earnings reports from companies like AngioDynamics, Grindr